Correction: Lu, W. et al. SOOCP: A Platform for Data and Analysis of Space Object Optical Characteristic Information. 2019, 10, 296

Lu, Wanjie; Xu, Qing; Lan, Chaozhen

doi:10.3390/info11030139

Cited by 3 publications

(16 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 42 publications and 6 abstracts met inclusion criteria, including 43 trials and 5 follow-up studies, from which we extracted 54 study arms; 5431 patients were included overall in the 43 trials (4020 males [74.0%]; median age range, 55-70 years) (Table; eTable 3 and eFigure 1 in Supplement 1). There were 8 RCTs comparing neoadjuvant chemoimmunotherapy with chemotherapy, namely CheckMate 816, KEYNOTE-671, NADIM II, AEGEAN, Neotorch, Checkmate 77T, TD-FOREKNOW, and RATIONALE 315 (Table). Across 3387 patients (2582 males [76.2%]; median age range, 61-66 years) included in 8 RCTs, there were 1688 patients (49.8%) treated with chemotherapy, 1699 patients (50.2%) treated with chemoimmunotherapy, 1882 patients (55.6%) who had squamous histology, and 2443 patients (72.1%) who had stage III disease.…”

Section: Resultsmentioning

confidence: 99%

“…There were 8 RCTs comparing neoadjuvant chemoimmunotherapy with chemotherapy, namely CheckMate 816, KEYNOTE-671, NADIM II, AEGEAN, Neotorch, Checkmate 77T, TD-FOREKNOW, and RATIONALE 315 (Table). Across 3387 patients (2582 males [76.2%]; median age range, 61-66 years) included in 8 RCTs, there were 1688 patients (49.8%) treated with chemotherapy, 1699 patients (50.2%) treated with chemoimmunotherapy, 1882 patients (55.6%) who had squamous histology, and 2443 patients (72.1%) who had stage III disease. Across all studies, there were 27 neoadjuvant chemotherapy and 27 neoadjuvant chemoimmunotherapy arms; 21 arms included only patients with stage III disease.…”

Section: Resultsmentioning

confidence: 99%

“…Across 3387 patients (2582 males [76.2%]; median age range, 61-66 years) included in 8 RCTs, there were 1688 patients (49.8%) treated with chemotherapy, 1699 patients (50.2%) treated with chemoimmunotherapy, 1882 patients (55.6%) who had squamous histology, and 2443 patients (72.1%) who had stage III disease. Across all studies, there were 27 neoadjuvant chemotherapy and 27 neoadjuvant chemoimmunotherapy arms; 21 arms included only patients with stage III disease. Studies ranged from 10 patients to 400 patients per arm, and there were 2347 patients assigned to neoadjuvant chemoimmunotherapy and 3084 patients assigned to neoadjuvant chemotherapy.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Neoadjuvant Chemoimmunotherapy for NSCLC

Sorin,

Prosty,

Ghaleb

et al. 2024

JAMA Oncol

View full text Add to dashboard Cite

ImportanceTo date, no meta-analyses have comprehensively assessed the association of neoadjuvant chemoimmunotherapy with clinical outcomes in non–small cell lung cancer (NSCLC) in randomized and nonrandomized settings. In addition, there exists controversy concerning the efficacy of neoadjuvant chemoimmunotherapy for patients with NSCLC with programmed cell death 1 ligand 1 (PD-L1) levels less than 1%.ObjectiveTo compare neoadjuvant chemoimmunotherapy with chemotherapy by adverse events and surgical, pathological, and efficacy outcomes using recently published randomized clinical trials and nonrandomized trials.Data SourcesMEDLINE and Embase were systematically searched from January 1, 2013, to October 25, 2023, for all clinical trials of neoadjuvant chemoimmunotherapy and chemotherapy that included at least 10 patients.Study SelectionObservational studies and trials reporting the use of neoadjuvant radiotherapy, including chemoradiotherapy, molecular targeted therapy, or immunotherapy monotherapy, were excluded.Main Outcomes and MeasuresSurgical, pathological, and efficacy end points and adverse events were pooled using a random-effects meta-analysis.ResultsAmong 43 eligible trials comprising 5431 patients (4020 males [74.0%]; median age range, 55-70 years), there were 8 randomized clinical trials with 3387 patients. For randomized clinical trials, pooled overall survival (hazard ratio, 0.65; 95% CI, 0.54-0.79; I2 = 0%), event-free survival (hazard ratio, 0.59; 95% CI, 0.52-0.67; I2 = 14.9%), major pathological response (risk ratio, 3.42; 95% CI, 2.83-4.15; I2 = 31.2%), and complete pathological response (risk ratio, 5.52; 95% CI, 4.25-7.15; I2 = 27.4%) favored neoadjuvant chemoimmunotherapy over neoadjuvant chemotherapy. For patients with baseline tumor PD-L1 levels less than 1%, there was a significant benefit in event-free survival for neoadjuvant chemoimmunotherapy compared with chemotherapy (hazard ratio, 0.74; 95% CI, 0.62-0.89; I2 = 0%).Conclusion and RelevanceThis study found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes. These findings suggest that patients with resectable NSCLC with tumor PD-L1 levels less than 1% may have an event-free survival benefit with neoadjuvant chemoimmunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant Chemoimmunotherapy for NSCLC

Sorin,

Prosty,

Ghaleb

et al. 2024

JAMA Oncol

View full text Add to dashboard Cite

show abstract

“…The NEOTORCH study was a similarly designed trial conducted entirely in China, comparing preoperative chemotherapy with the ICI toripalimab or placebo added to 3 cycles of platinum-based chemotherapy, then followed by planned surgery, adjuvant chemotherapy with toripalimab or placebo for 1 additional cycle, and then adjuvant toripalimab or placebo alone to complete a year of systemic therapy. Results reported thus far, with a median follow-up of 18.3 months, are limited to 404 patients with stage III NSCLC by AJCC Staging Manual eighth edition criteria and demonstrate a significant improvement in EFS by independent review committee (HR, 0.40; 2-year EFS 66.7% vs 46.1%; P < .001) most pronounced in patients with PD-L1 higher than 50% (HR, 0.31) or PD-L1 of 1% to 49% (0.31) compared with those with PD-L1 expression lower than 1% or not evaluable (HR, 0.59).…”

Section: Perioperative Chemoimmunotherapy and The Incremental Value O...mentioning

confidence: 99%

Rapid Advances in Resectable Non–Small Cell Lung Cancer

West,

Kim

2024

JAMA Oncol

View full text Add to dashboard Cite

ImportanceA series of high-profile clinical trials for patients with resectable early-stage non–small cell lung cancer (NSCLC) have recently changed the standard of care in this setting. Specifically, studies have demonstrated statistically and clinically significant improvements in efficacy with the targeted therapy for adjuvant osimertinib in patients with resected NSCLC harboring an epidermal growth factor receptor (EGFR) genomic abnormality (GA), whereas trials with chemotherapy combined with nivolumab in the neoadjuvant setting and others testing atezolizumab or pembrolizumab as adjuvant therapy have all demonstrated improvements in event-free survival (EFS) (for neoadjuvant therapy) or disease-free survival (DFS) (for adjuvant therapy). These trials introduce many open questions about how to apply these findings in clinical practice.ObservationsTreatment with adjuvant osimertinib for 3 years was associated with significant improvement in both DFS and overall survival (OS), but the erosion of the DFS benefit after the duration of treatment ends suggests a potential value for more longitudinal treatment. The potential value of highly effective targeted therapies as adjuvant therapy for other GAs has a compelling rationale but no data at this time. Adjuvant atezolizumab or pembrolizumab, generally administered for 1 year after postoperative chemotherapy, are appropriate considerations, but only atezolizumab for patients with tumor programmed death-ligand 1 (PD-L1) levels of 50% has demonstrated a benefit in OS. Neoadjuvant chemotherapy with nivolumab offers a strong EFS benefit, a shorter interval of treatment, and radiographic and pathologic feedback for patients with resectable stage IB to IIIA NSCLC, although very recent randomized clinical trials of perioperative immunotherapy both combined with chemotherapy preoperatively and administered postoperatively highlight the debatable value of adjuvant immunotherapy after prior chemoimmunotherapy. Improved tumor shrinkage rates with neoadjuvant chemoimmunotherapy suggest the possibility that criteria for resectability may potentially be redefined in anticipation of a good response to neoadjuvant chemoimmunotherapy.Conclusions and RelevanceDevelopments in resectable NSCLC have arrived so rapidly that they have also created practical challenges of identifying optimal patients and prioritizing options among these new competing standards. In some cases, practical management requires clinical judgment and discussion with the patient to cover the gaps in prospective data. Caution should be exerted when extrapolating beyond the available data.

show abstract

“…[6][7][8][9][10][11][12][13][14][15][16][17] Despite such advantages of the coreshell NW structure, the IQE of the 3D MQSs device is still lower than that of a conventional 2D multiple-quantum-wells (MQWs) device. 18,19) This is probably because the impurity composition and concentrations of each layer have not been optimized and fully studied. [20][21][22][23] Furthermore, the light extraction efficiency (LEE) of the 3D MQSs device is reported to be lower than that of the 2D MQWs device due to greater light absorption in the indium-tin-oxide (ITO) layer.…”

Section: Introductionmentioning

confidence: 99%

Analysis of impurity doping in tunnel junction grown on core–shell structure composed of GaInN/GaN multiple-quantum-shells and GaN nanowire

Sone¹,

Jinno²,

Miyamoto³

et al. 2021

Jpn. J. Appl. Phys.

View full text Add to dashboard Cite

This study aimed to investigate and analyze the impurity doping characteristics in tunnel junctions (TJs) grown on core–shell structures, comprising GaInN/GaN multiple-quantum-shells (MQSs) and GaN nanowires. To this end, the impurity, structural, and electrical properties of the samples were characterized by scanning electron microscopy, scanning transmission electron microscopy, atom probe tomography (APT), nanoscale secondary ion mass spectrometry (NanoSIMS), and electroluminescence of the device which was fabricated for a prototype laser device to demonstrate an electrical operation of the MQSs layer. From the experimental results of NanoSIMS and APT, we demonstrated that the Mg-related problems in the TJ, such as the diffusion to the n++-GaN layer from the p+-GaN layer and formation of clusters in p+-GaN, are critical. Consequently, they cause a high operating voltage and dot-like spot emission of the light-emitting device. Based on the analysis, we suggested remedies and strategies to further improve the TJs that work well.

show abstract

Correction: Lu, W. et al. SOOCP: A Platform for Data and Analysis of Space Object Optical Characteristic Information. 2019, 10, 296

Abstract: After publication of the research paper [1], two identical figures were pointed out: Figure 18 and Figure 19. In fact, the wrong figure was Figure 19[...]

Cited by 3 publications

References 1 publication

Neoadjuvant Chemoimmunotherapy for NSCLC

Neoadjuvant Chemoimmunotherapy for NSCLC

Rapid Advances in Resectable Non–Small Cell Lung Cancer

Analysis of impurity doping in tunnel junction grown on core–shell structure composed of GaInN/GaN multiple-quantum-shells and GaN nanowire

Contact Info

Product

Resources

About